ReviewGastroenterologia y hepatologia2020
Liver transplant immunosuppression during the covid-19 pandemic.
Review in Gastroenterologia y hepatologia, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 20 citations in OpenAlex.
- Assessing the associations between immunosuppressant use and COVID-19 severity in patients with autoimmune hepatitis.World journal of hepatology · 2026Article
- The Impact and Evolution of COVID-19 on Liver Transplant Recipients Throughout the Pandemic "Waves" in a Single Center.Viruses · 2025Observational
- Outcomes of COVID-19 in 24 hospitalized liver transplant recipients: an observational study.BMC infectious diseases · 2024Observational
- COVID-19 Hospitalization in Solid Organ Transplant Recipients on Immunosuppressive Therapy.JAMA network open · 2023Article
- The impact of COVID-19 on liver transplantation: challenges and perspectives.Therapeutic advances in gastroenterology · 2023Review
- Coronavirus Precautions: Experience of High Volume Liver Transplant Institute.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2022Article
- From advanced disease to transplantation: an overview of the liver at the time of COVID-19 pandemic.Internal and emergency medicine · 2022Review
- Case report: One pediatric liver-transplant recipient with SARS-CoV-2 infection suffering unexplained mixed acidosis.Frontiers in medicine · 2022Article
- Critical Update on the Diagnosis and Management of COVID-19 in Advanced Cirrhosis and Liver Transplant Recipients.Journal of clinical and translational hepatology · 2021Review
- Managing liver transplantation during the COVID-19 pandemic: A survey among transplant centers in the Southeast United States.World journal of hepatology · 2021Article
- Solid organ transplantations and COVID-19 disease.World journal of transplantation · 2021Review
- Impact of COVID-19 pandemic on liver, liver diseases, and liver transplantation programs in intensive care units.World journal of hepatology · 2021Review
- COVID-19: biologic and immunosuppressive therapy in gastroenterology and hepatology.Nature reviews. Gastroenterology & hepatology · 2021Review
- Abnormal Liver Biochemistry Tests and Acute Liver Injury in COVID-19 Patients: Current Evidence and Potential Pathogenesis.Diseases (Basel, Switzerland) · 2021Review
- Management of liver disease patients in different clinical situations during COVID-19 pandemic.Egyptian liver journal · 2021Review
- Impact of COVID-19 Pandemic on Pediatrics and Pediatric Transplantation Programs.Frontiers in pediatrics · 2020Article
- COVID-19 infection in a child following liver transplantation.Anaesthesia reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SARS-CoV-2 infection has produced a pandemic with serious consequences for our health care system. Although liver transplant patients represent only a minority of the population, the hepatologists who follow these patients have tried to coordinate efforts to produce a protocol the management of immunosuppression during SARS-CoV-2 infection. Although there are no solid studies to support general recommendations, experiences with other viral infections (hepatitis C, cytomegalovirus) suggest that management of immunosuppression without mycophenolate mofetil or m-Tor inhibitors (drugs that are also associated with leukopenia and lymphopenia) may be beneficial. It is also important to pay attention to possible drug interactions, especially in the case of tacrolimus, with some of the treatments with antiviral effect given in the context of COVID 19 (lopinavir/ritonavir, azithromycin). Finally, the immunosuppressive effect of immunomodulating drugs (tocilizumab and similar) administered to patients with severe lung disease should be taken into account. The mechanisms of action of the different immunosuppressive drugs are reviewed in this article, as well as their potential effect on SARS-CoV-2 infection, and suggests guidelines for the management of immunosuppression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.